Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parathymosin (PTMS) is a small, highly conserved, acidic nuclear protein that is widely expressed in various tissues, including the brain, where it is secreted by hypothalamic neural stem/progenitor cells and neurons[1]. PTMS is rapidly transferred into nuclei of recipient cells, where it may regulate chromatin organization through its histone-binding ability, particularly by modulating the association of linker histone H1 with nucleosomes[4]. It is involved in the regulation of transcription and in the negative regulation of cell death processes, and has been shown to mediate neuroprotective functions, including inhibition of cellular senescence in the brain[1][3]. PTMS may also play a role in immune function by interfering with prothymosin alpha-mediated pathways[3]. Although it is biologically significant and has been investigated for its potential protective roles in aging and neurodegeneration, there is no direct evidence that parathymosin is a receptor, therapeutic target, or a molecule with known interacting drugs or biomarker status. Its precise mechanisms and clinical utility are still under investigation[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parathymosin (PTMS).